Clinical trials: Sjögren's Syndrome
Sjögren's Syndrome, Xerostomia
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
Chronic inflammation that comprises the exocrine glands' function leads to xerophthalmia and xerostomia in Sjögren's syndrome. The oral consequences range widely and they are related to decreased salivary output.
- Trial name
- NCT00873496
- Testing
- Hydroxychloroquine
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Ege University
Sjogren's Syndrome
Sjogren's Mini-Pill Oral and Gut Microbiome Study
The goal of this observational study is to characterize and compare region-specific gastrointestinal, stool, oral, and periodontal microbiomes in adults with Sjögren's disease and healthy controls using ingestible mini-pill…
- Trial name
- NCT07732582
- Testing
- Mini-Pill
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Tufts University
Dry Eye Disease
Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom
To study the effectiveness of 0.05% cyclosporine A eye drops in combination with smart plug absorbable lacrimal duct plugs in the monotherapy of cyclosporine for SSDE.
- Trial name
- NCT07171710
- Testing
- 0.05% Cyclosporine Eye Drops, Smart plug absorbable lacrimal duct plugs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Eye Hospital
Rheumatoid Arthritis, Spondyloarthritis
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
The prognosis of rheumatic diseases has improved considerably with development of therapy. However, infections are considered the most important cause of morbidity and mortality in this group of patients.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM)
- Trial name
- NCT01151644
- Testing
- Anti-pandemic H1N1 influenza vaccine
- Where
- Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Sjogren Syndrome, Dry Syndrome
Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)
Prospective multicenter cross-sectional study evaluating ultrasound of the main salivary glands (2 parotid and 2 submandibular) in patients with Sjögren's disease compared with patients with other connective diseases (rheumatoid…
- Conditions
- Sjogren Syndrome, Dry Syndrome, Lupus, Scleroderma
- Trial name
- COUGAR (NCT06680310)
- Where
- France
- Volunteers
- 501 people
- Sponsor
- University Hospital, Brest
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Sjogren's Syndrome, Mesenchymal Stem Cells
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
This study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (MSCT) to treat patients with diagnosis of primary Sjögren's Syndrome (pSS) who have been resistant to multiple standard treatments.
- Trial name
- NCT00953485
- Testing
- Allogeneic Mesenchymal Stem Cells (AlloMSC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Primary Sjögren's Syndrome
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method…
- Trial name
- NCT02495129
- Testing
- VAY736 lower dose, VAY736 higher dose
- Sponsor
- Novartis Pharmaceuticals